Skip to main content

Advances in Pancreatic Cancer Immunotherapy

  • 1st Edition - May 1, 2027
  • Latest edition
  • Editors: Vivek P. Chavda, Amit K. Tiwari, Zhe-Sheng Chen
  • Language: English

Advances in Pancreatic Cancer Immunotherapy explores cutting-edge strategies to combat one of the most lethal malignancies. This book provides a focused, comprehensive resour… Read more

Description

Advances in Pancreatic Cancer Immunotherapy explores cutting-edge strategies to combat one of the most lethal malignancies. This book provides a focused, comprehensive resource on immunotherapy innovations for pancreatic cancer. It examines the tumor microenvironment, mechanisms of immune evasion, and the latest therapeutic modalities, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. Chapters cover clinical and preclinical studies, combination strategies, biomarker-driven personalization, and regulatory considerations, offering a deep dive into both foundational science and translational applications. For researchers, clinicians, and graduate students, this book delivers actionable insights into overcoming treatment resistance, integrating immunotherapy into clinical practice, and shaping future research directions. It serves as an essential reference for understanding and applying immunotherapeutic advances to improve patient outcomes.

Key features

  • Provides an in-depth analysis of immunotherapy mechanisms and their role in pancreatic cancer
  • Highlights the latest innovations, including checkpoint inhibitors, cancer vaccines, and CAR T-cell therapies
  • Examines clinical applications, challenges, and future directions for personalized treatment strategies

Readership

Healthcare professionals, oncology researchers, graduate students, and pharmaceutical/biotech professionals specializing in cancer immunotherapy

Table of contents

1. Introduction to Pancreatic Cancer

2. The Tumor Microenvironment in Pancreatic Cancer

3. Mechanisms of Immune Evasion in Pancreatic Cancer

4. Overview of Immunotherapy Approaches

5. Checkpoint Inhibitors in Pancreatic Cancer Treatment

6. Cancer Vaccines: Targeting Pancreatic Tumors

7. Adoptive Cell Transfer: CAR T-Cell Therapy

8. Combination Therapies: Enhancing Immunotherapy Efficacy

9. Personalized Immunotherapy Approaches

10. Challenges and Limitations of Immunotherapy in Pancreatic Cancer

11. Emerging Therapies and Future Directions

12. Regulatory Considerations and Biosimilars for Immunotherapy Products

13. Patient Perspectives and Quality of Life Considerations

Product details

  • Edition: 1
  • Latest edition
  • Published: May 1, 2027
  • Language: English

About the editors

VC

Vivek P. Chavda

Vivek P. Chavda is an Assistant Professor (Selection Grade) in the Department of Pharmaceutics and Pharmaceutical Technology at L. M. College of Pharmacy, Ahmedabad, Gujarat, India. He earned Bachelor and Master of Pharmacy degrees and was a Gold Medallist at Gujarat Technological University. Before entering academia, he spent several years in the Biologics industry, contributing to R&D and regulatory filings for biologics. His scholarly output includes numerous peer‑reviewed articles, several books and book chapters, and ongoing writings in newsletters. His research spans the development of biologics processes and formulations, medical device development, nano diagnostics and noncarrier formulations, long-acting parenteral formulations, and nano vaccines. He also has patent assets in development and a record of industry-focused publications.

Affiliations and expertise
Assistant Professor, Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, Gujarat, India

AT

Amit K. Tiwari

Dr. Amit K. Tiwari is a full Professor and Associate Dean of Research and Graduate Studies at UAMS. He completed graduate studies at St. John's University, NY, and pursued postdoctoral training in pharmacokinetics at Mount Sinai School of Medicine. A board-certified toxicologist and Diplomate of the American Board of Toxicology, he serves on multiple advisory boards and holds honorary professorships from Bundelkhand University and Bharati Vidyapeeth University. His work spans discovery, design, development, and delivery of targeted anticancer therapeutics addressing multidrug resistance. He has authored extensively in peer-reviewed journals, contributed book chapters, and presented at numerous conferences. He also reviews for many journals and chairs editorial duties, including as Associate Editor for Frontiers in Pharmacology and Frontiers in Oncology, while serving on additional editorial boards.

Affiliations and expertise
Professor and Associate Dean of Research and Graduate Studies, University of Arkansas for Medical Sciences, Little Rock, USA

ZC

Zhe-Sheng Chen

Zhe-Sheng Chen, PhD., opened the St. John’s University’s first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen has over 170 papers published, co-edited Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy book (Elsevier), and holds several patents.
Affiliations and expertise
St. John's University, New York, USA